Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as a tablet for oral use. It treats hypertension and heart failure, particularly after myocardial infarction, in adult patients by reducing sodium retention and potassium loss.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, ensuring product integrity from manufacturing to the end‑user.

Eplerenone is used in cardiovascular conditions that involve aldosterone‑mediated fluid retention.

- Hypertension: lowers blood pressure by decreasing sodium reabsorption and water retention. - Heart failure (post‑myocardial infarction): improves survival and reduces hospitalizations by limiting adverse cardiac remodeling. - Heart failure with reduced ejection fraction: decreases morbidity and mortality in patients with systolic dysfunction.

Eplerenone may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Dizziness: sensation of light‑headedness. - Headache: mild to moderate cranial pain. - Fatigue: generalized tiredness. - Nausea: upset stomach. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe hyperkalemia: potentially life‑threatening potassium excess. - Renal impairment: decline in kidney function. - Angioedema: swelling of face, lips, or airway. - Hepatic dysfunction: abnormal liver enzyme elevations. - Menstrual irregularities: changes in cycle patterns. - Anaphylactic reaction: rare severe allergic response.

When prescribing eplerenone, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor serum potassium: check levels before initiation and periodically during therapy. - Assess renal function: evaluate creatinine clearance prior to start and during treatment. - Use caution in diabetes: patients may have altered potassium handling. - Avoid in pregnancy: category D indicates potential fetal risk; discontinue if pregnancy occurs. - Adjust dose in elderly: start with lower dose and titrate cautiously. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Eplerenone interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use can cause dangerous hyperkalemia. - Potassium‑sparing diuretics or supplements: increase risk of severe hyperkalemia. - Cyclosporine: may raise eplerenone plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: can impair renal function and elevate potassium. - Digoxin: altered renal clearance may require dose adjustment. - Lithium: concurrent use may increase lithium levels and toxicity.